Prostate Cancer Screening IMPACT ECHO

Prostate Cancer is the 2nd leading cause of cancer death in U.S. men with an estimated 34,700 deaths from prostate cancer expected in 2023. Since 2011, the diagnosis of advanced-stage prostate cancer has increased 4%-5% annually. Shared decision-making and appropriate PSA testing is underutilized even with high-risk patients. Too many patients lack the access and opportunity for diagnosis at an early stage when prostate cancer has a 99% relative survival rate. Alternatively, diagnosis of prostate cancer at a late stage has a 32% relative survival rate. We must address these shifts to improve prostate cancer outcomes for all men, especially for Black men who carry a disproportionate burden of occurrences and deaths in the U.S. This ECHO is part of our IMPACT Initiative – Improving Mortality from Prostate Cancer Together to improve outcomes for all and reverse disparities for Black men. We will bring together a multi-disciplinary team of prostate cancer screening experts and teams from 10 FQHCs/other safety-net primary care clinics serving a large population of Black/African American patients.